Tokyo University of Pharmacy and Life Sciences · Department of Pharmacy / Faculty of Pharmaceutical Sciences

Research keywordsCrohn's disease・inflammatory bowel disease・vedolizumab pharmacokinetics・adalimumab therapy optimization・model-informed precision dosing・tumor necrosis factor inhibitors・therapeutic response prediction・medication reconciliation

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn's disease using summary level data and its application to model-informed precision dosing.2026 · The Journal of pharmacy and pharmacology
• A prediction method for the individual serum concentration and therapeutic effect for optimizing adalimumab therapy in inflammatory bowel disease.2025 · The Journal of pharmacy and pharmacology
• Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study.2022 · European journal of gastroenterology & hepatology
• Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling2020 · European Journal of Pharmaceutical Sciences

• Official profile